Abstract
Background: Ginsenoside Rg1, the active ingredient of natural plants, has been proved to have anti-liver fibrosis activity. However, the specific mechanism behind these effects has not been determined. This study aims to inverstigate the specific mechanism of the antihepatic fibrosis of ginsenoside Rg1. Methods: The rat model of hepatic fibrosis induced by Concanavalin A (Con A) were established and hepatic stellate cells were isolated. Then hepatic fibrosis and cell damage were evaluated and inverstigated the mechanism. Findings: We found that the anti-hepatic fibrosis effect of ginsenoside Rg1 was related to JAK2/STAT3 signaling pathway and IL-1β, IL-6, IL-10. In addition, the expression of IL-1β, IL-6, IL-10, α-SMA, TGF-β, CollaⅠ and CollaⅡ mRNA in rats treated with different doses of ginsenoside Rg1 for 8 weeks were decreased compared with model group, and mRNA expression of IL-10 was increased, which was associated with drug dosage. Forthermore, the expression of p-JAK2, p-STAT3, Caspase3, α-SMA, TGF-β, CollaⅠ and CollaⅡ protein decreased, and the degree of decrease was correlated with the dosage of administration. Similar results were detected by Immunohistochemistry. The expression of JAK2 and STAT3 protein were not changed significantly. Besides, flow cytometry revealed that ginsenoside Rg1 could promote hepatic stellate cell (HSC) apoptosis. Interpretation: TTaken together, our results indicate that the anti-fibrotic effect of ginsenoside Rg1 is related to JAK2/STAT3 signaling pathway and IL-1β, IL-6, IL-10, and ginsenoside Rg1 is a potential drug against liver fibrosis. Funding Statement: This study was supported by the National Science Foundation of China (grant 81270498) and the National Science Foundation of China (grant 81500473). Declaration of Interests: The authors declare no conflict of interest Ethics Approval Statement: During these studies, all animal procedures were conducted in accordance with the Anhui Medical University Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed the Institutional Animal Care and Use Committee either at Anhui Medical University or by the ethical review process at the institution where the work was performed. The experimental protocol for this study was approved by the Anhui Medical University of Animal welfare, Ethics and Strategy and Anhui Province Key Laboratory of Major Autoimmune Diseases, Hefei, China.